Pérez-Cebrián Manuela, Suárez-Varela María M Morales, Font-Noguera Isabel, Monte-Boquet Emilio, Poveda-Andrés Jose Luís, Martín-Moreno Jose María, Rubio-López Nuria, Ruiz-Rojo Elias, Llopis-González Agustín
Pharmacy Service. University Hospital La Fe, Valencia, Spain.
Unit of Public Health and Environmental Care, Department of Preventive Medicine, University of Valencia, Spain. ; CIBER of Epidemiology and Public Health (CIBERESP), Madrid, Spain. ; Center for Public Health Research (CSISP), Valencia, Spain.
Iran J Pharm Res. 2015 Summer;14(3):857-64.
Indications for linezolid use are nosocomial or community-acquired pneumonia and skin infections or soft tissue infection caused by gram-positive microorganisms, but new recommendations may emerge. It is important to balance benefits with risks because severe adverse events have been described in patients taking linezolid treatment. Accordingly, we evaluated the suitability of linezolid prescription according to approval of indication by evaluating the presence of drug-related problems (DRP) in a University hospital. DRP were identified in 36 patients (50.0%). In most cases, they were related to known or established indications (15 patients, 20.8%), to safety (5 patients, 6.9%), and to both in others (16 patients, 22.2%). No DRP were recorded, which modified linezolid efficacy. DRP were significantly higher in the patients treated by an approved indication in Spain (63.3%) than in those treated by an unapproved indication in Spain (28.6%). We concluded that new studies about extending linezolid indications may be necessary.
利奈唑胺的适应证为医院获得性或社区获得性肺炎以及由革兰氏阳性微生物引起的皮肤感染或软组织感染,但可能会出现新的推荐意见。由于服用利奈唑胺治疗的患者中曾有严重不良事件的报道,因此权衡利弊很重要。据此,我们通过评估某大学医院中药物相关问题(DRP)的存在情况,根据适应证批准情况评估了利奈唑胺处方的适宜性。在36例患者(50.0%)中发现了DRP。在大多数情况下,这些问题与已知或既定适应证相关(15例患者,20.8%)、与安全性相关(5例患者,6.9%),在其他患者中则与两者都相关(16例患者,22.2%)。未记录到改变利奈唑胺疗效的DRP。在西班牙,经批准适应证治疗的患者中DRP显著高于未经批准适应证治疗的患者(63.3%比28.6%)。我们得出结论,可能需要开展关于扩大利奈唑胺适应证的新研究。